![BeardBros_BlogImages [Recovered]](data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjU2MCAyOTIiIHdpZHRoPSIyNTYwIiBoZWlnaHQ9IjI5MiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj48L3N2Zz4=)
Key Takeaways
- The Senate passed a funding bill delaying the federal hemp ban until December 11, providing temporary relief for the hemp industry.
- This 29-day reprieve is insufficient for establishing a comprehensive regulatory framework for hemp-derived products.
- The amendment to remove the delay faced opposition, highlighting the contentious nature of the federal hemp ban debate.
- The White House played a surprising role, advocating for the hemp delay despite previously supporting the ban.
- Congress must decide on the proposed measures before December 11, or the ban on most hemp products will take effect.
The Senate voted 90-6 in an overnight session on Saturday, to pass a short-term government funding bill that keeps federal agencies running through December 11 and, buried inside it, gives the hemp industry a 29-day reprieve from an impending federal ban on most intoxicating hemp-derived THC products.
That reprieve is not a solution. Congress has yet to craft a regulatory framework with any real staying power. What lawmakers did manage to do is kick a very expensive, very contentious can down the road by less than a month. For a hemp industry that the U.S. Hemp Roundtable estimates at approximately $28 billion in annual market value, supporting more than 300,000 jobs, 29 days is not an insignificant amount of time. But it is not a policy either.
The fight over the hemp provision nearly derailed the entire spending bill. An internal Republican standoff, an unusual level of direct White House involvement, a bipartisan coalition of 35 attorneys general, and a personal phone call from President Trump to at least one senator who refused to back down all converged on what many assumed would be a routine appropriations process. It was not routine at all.
What Does the Senate Continuing Resolution Hemp Provision Actually Do?
Section 2019 of the Senate’s continuing resolution limits the reach of Section 781 of Public Law 119-37 until December 11th. Section 781 is the legislation Trump signed in November 2025 that redefined hemp to make only products containing 0.4 milligrams of total THC per container federally legal after November 12, 2026. That threshold is dramatically lower than the previous standard set by the 2018 Farm Bill, which allowed hemp derivatives containing less than 0.3 percent delta-9 THC on a dry-weight basis.
The Senate CR pauses that new definition for most hemp products. There is a carve-out, though. Synthetic cannabinoids “that are not capable of being naturally produced by a Cannabis sativa L. plant” do not benefit from the delay. Those products still face recriminalization on November 12, regardless of whether the full bill becomes law. Hemp businesses relying on fully synthetic cannabinoids should not count this provision as protection.
For plant-derived cannabinoid products, including delta-8, delta-9, CBD, and full-spectrum items, the Senate language buys roughly a month of breathing room while Congress continues debating a longer-term approach.
How Did the 2018 Farm Bill Create the “Hemp Loophole”?
To understand why any of this is happening, you have to go back to 2018. The Farm Bill that Trump signed during his first term removed hemp from the federal controlled substances list, defining it as cannabis with less than 0.3 percent delta-9 THC on a dry-weight basis. That opened a legal pathway for hemp-derived CBD, and shortly after, for delta-8, delta-10, and other cannabinoid products that companies began extracting and synthesizing from hemp at scale.
The industry grew fast. Products ended up not just in dispensaries but in gas stations, convenience stores, and major retailers including Target. Many of those products could deliver a marijuana-like high without technically being classified as marijuana. Packaging frequently mimicked popular snack brands. Age restrictions were inconsistent. Testing requirements were minimal or nonexistent.
Critics called it the “hemp loophole.” In November 2025, Congress moved to close it, tucking a redefinition of hemp into a broader spending package. Trump signed it, and the clock started ticking toward November 12th.
Who Is Sen. Ted Budd, and Why Did He Try to Strip the Delay?
Sen. Ted Budd (R-NC) filed an amendment that would have removed the hemp delay provision from the continuing resolution entirely. He gathered 13 co-sponsors, including Democratic Sen. Kirsten Gillibrand of New York. The Senate rejected the amendment, but not without a fight.
“If substances cause intoxication like marijuana, then they should be regulated as such, not given a free pass as hemp,” Budd said during a floor speech. “There is no loophole worth putting a child’s well-being at risk.”
Sen. Tom Cotton of Arkansas took a similar position, reportedly describing hemp-derived THC products as “gas-station marijuana candy” during a closed-door Republican lunch on August 5.
What Role Did the White House Play in Keeping the Hemp Delay in the Bill?
This is where the story gets more complicated. The Trump administration’s involvement in pushing for the delay caught multiple Senate Republicans off guard. Several senators described the White House position as unexpected, given that Trump himself signed the ban into law less than a year earlier.
Trump posted on Truth Social in April 2026, calling on Congress to update the law so Americans could keep accessing full-spectrum CBD products. White House Budget Director Russell Vought wrote to House Speaker Mike Johnson in June asking for “fair treatment of hemp products.” The Office of Management and Budget included hemp language in its wish list of “anomalies” for the stopgap bill sent to lawmakers in July.
Then, according to multiple sources with knowledge of the situation, Trump personally called Budd ahead of the senator’s floor push in an attempt to walk him back. Budd’s spokesman, Christian McMullen, confirmed the call took place, describing it as “very friendly” and touching on multiple topics. McMullen said there was “not an explicit ask made to Sen. Budd to drop the amendment,” but that the hemp issue “certainly came up.”
White House Director of Legislative Affairs James Braid took things further. According to reporting from Punchbowl News and NBC News, Braid got into a tense exchange with Republican senators during a closed-door lunch on August 5, becoming especially contentious with Cotton. Braid committed at that meeting that there would be no further extensions of the hemp ban’s effective date if the current delay passed.
What Is the Susie Wiles Connection, and How Did the White House Respond?
The New York Times reported on August 5th, that the White House pressure campaign to keep hemp products legal was “led in part” by Bret Worley, president and CEO of Colorado-based MC Nutraceuticals, a hemp products company. Worley married Susie Wiles’s daughter Caroline in June at the Trump Winery in Charlottesville. Wiles is Trump’s chief of staff.
The White House pushed back. Spokesperson Kush Desai told the Times that Worley “had nothing to do” with the president’s position on hemp. Desai told NBC News that “the only interest guiding the Trump administration’s decision-making is the best interest of the American people.” Desai also said that Wiles, when meeting with lawmakers to advocate for the continuing resolution, did not specifically mention the hemp provision and “has never lobbied in favor of this or any other position on hemp with Capitol Hill.”
The administration’s stated rationale centers on veterans and patients who rely on hemp-derived products for medicinal purposes, and on what it describes as a “Gold Science Standard-based framework” for hemp regulation. The Centers for Medicare and Medicaid Services, launched a program in April 2026 covering up to $500 worth of hemp-derived products annually for eligible Medicare patients.
What Did 35 Attorneys General Say About the Hemp Ban Delay?
On August 4th, attorneys general from 34 states and the U.S. Virgin Islands sent a joint letter to the top four congressional leaders asking them to reject the Senate provision delaying the ban. The letter was led by Arkansas Attorney General Tim Griffin, Indiana Attorney General Todd Rokita, Connecticut Attorney General William Tong, and New Mexico Attorney General Raúl Torrez.
The AGs argued that the November 2025 redefinition of hemp “protected consumers, provided much-needed regulatory clarity, and preserved legitimate industrial, agricultural, and nonintoxicating hemp markets.” Their position was that any delay would trigger regulatory chaos at the state level, undo enforcement alignment work already underway, and increase minors’ access to intoxicating products.
This letter followed an earlier October 2025 effort, when a separate coalition of 39 attorneys general asked Congress to clarify the federal definition of hemp and restrict the ongoing sale of synthetic cannabinoids marketed to children.
What Happens Now That the Senate Has Passed the Bill?
The Senate passed the continuing resolution, but the bill still has to clear the House before it reaches Trump’s desk. The House passed its own version of the continuing resolution last month without any hemp provisions at all. When lawmakers return from recess in September, the House will decide whether to accept the Senate’s hemp language, strip it out, or negotiate a compromise.
If December 11 arrives without a longer-term fix, roughly 95 percent of hemp-derived cannabinoid products would become federally unlawful under the 0.4 milligram per container threshold, according to industry estimates. That is not a regulatory adjustment. For most businesses operating in the hemp-derived cannabinoid space, it would effectively eliminate their product lines under federal law.
Several longer-term legislative proposals are in circulation. Rep. Andy Barr (R-KY) filed a bipartisan bill alongside Rep. Angie Craig (D-MN) that would prevent recriminalization while establishing a regulatory framework covering manufacturing, labeling, sales, taxation, and a minimum purchase age of 21. Rep. James Comer (R-KY) is circulating a separate proposal that would also delay the ban while adding packaging requirements, testing rules, and age restrictions. Sens. Tim Sheehy (R-MT) and Amy Klobuchar (D-MN) are preparing to introduce a Senate companion bill. None of these proposals have cleared committee.
The December funding deadline is now the most realistic window for attaching a larger hemp fix to legislation with actual forward momentum.
What 29 Days Really Means for the Hemp Industry
Twenty-nine days is enough time to make inventory decisions, adjust supplier contracts, and plan around retail distribution agreements. It is not enough time to build a federal regulatory framework from scratch.
The hemp-derived cannabinoid market is approximately $28 billion in annual market value, according to industry groups. Before the November 2025 ban passed, analysts had projected the hemp market would grow from roughly $11 billion in 2025 to $47 billion by 2032. Those projections did not survive the law that Trump signed last fall.
Congress bought hemp businesses a month. The question for September is whether that month gets them anything more than another deadline.
Frequently Asked Questions
In November 2025, Trump signed legislation redefining hemp, limiting federally legal products to those containing no more than 0.4mg of total THC per container. Originally set to take effect on November 12, 2026, a Senate resolution passed on August 8, 2026 has pushed the deadline back to December 11, 2026 for most plant-derived hemp products.
The Senate CR excludes synthetic cannabinoids that cannabis plants cannot naturally produce. These products will be recriminalized on November 12, 2026, regardless of the House vote outcome.
The Trump administration has delayed hemp regulations to allow time for discussions on a long-term framework. The White House has cited veterans and patients who rely on hemp-derived products, and noted that a Medicare program launching in April 2026 will cover up to $500 annually in hemp-derived products for eligible patients.
Sen. Ted Budd (R-NC) filed an amendment to remove the hemp delay provision from the continuing resolution, gathering 13 co-sponsors, including Sen. Kirsten Gillibrand (D-NY). The Senate rejected it. Budd argued the ban should proceed as planned, pointing to a nearly 10-fold increase in cannabis-related emergency room visits by minors in North Carolina since 2017.
